In 463 patients over 60 with AML or high-risk MDS, adding quizartinib after intensive chemotherapy did not significantly improve overall survival (primary outcome) and raised non-relapse mortality; in a pre-planned FLT3-mutated subgroup (116), OS improved (HR 0.59).
RCTn = 463
Knapper et al. Combining quizartinib with intensive chemotherapy for older patients with newly diagnosed AML: results of the UK NCRI AML18 trial